ストックスクリーナーアプリを入手
48.24
0.24%
0.11
前日終値:
$48.13
開ける：
$47.73
24時間の取引高:
1.03M
Relative Volume:
0.72
時価総額：
$10.29B
収益：
$1.98B
当期純損益:
$83.59M
株価収益率:
128.98
EPS:
0.374
ネットキャッシュフロー:
$502.31M
1週間 パフォーマンス:
+1.51%
1か月 パフォーマンス:
+2.42%
6か月 パフォーマンス:
+2.94%
1年 パフォーマンス:
+11.21%
1日の値動き範囲:
$47.73
$48.47
1週間の範囲:
$47.35
$48.90
52週間の値動き範囲:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
QGEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
48.25 | 10.29B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
426.95 | 158.06B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
198.41 | 142.87B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.65 | 43.87B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.56 | 33.87B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
160.08 | 28.10B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-04 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | アップグレード | Jefferies | Hold → Buy |
| 2024-10-17 | ダウングレード | HSBC Securities | Buy → Hold |
| 2024-06-27 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-07 | アップグレード | Goldman | Neutral → Buy |
| 2023-09-12 | 開始されました | Robert W. Baird | Outperform |
| 2023-05-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-01-18 | アップグレード | DZ Bank | Hold → Buy |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-10-14 | 開始されました | Redburn | Buy |
| 2021-07-14 | ダウングレード | Kepler | Buy → Hold |
| 2021-06-03 | 開始されました | Goldman | Neutral |
| 2020-10-06 | 再開されました | BofA Securities | Buy |
| 2020-09-28 | アップグレード | Kepler | Hold → Buy |
| 2020-08-24 | アップグレード | Citigroup | Neutral → Buy |
| 2020-08-20 | 再開されました | JP Morgan | Overweight |
| 2020-08-17 | アップグレード | Berenberg | Hold → Buy |
| 2020-08-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2020-08-14 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | ダウングレード | Berenberg | Buy → Hold |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Neutral |
| 2019-12-26 | 再開されました | BofA/Merrill | Underperform |
| 2019-11-15 | 開始されました | Stifel | Hold |
| 2019-11-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-11-14 | アップグレード | JP Morgan | Underweight → Overweight |
| 2019-11-14 | アップグレード | Kepler | Reduce → Hold |
| 2019-10-17 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | ダウングレード | Kepler | Hold → Reduce |
| 2019-10-08 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-10-08 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Qiagen Nv (QGEN) 最新ニュース
Qiagen and Gencurix partner for oncology tests - MSN
Qiagen NV stock hits 52-week high at 48.82 USD By Investing.com - Investing.com South Africa
Qiagen Announces Managerial Share Transaction - TipRanks
Qiagen NV stock hits 52-week high at 48.82 USD - Investing.com
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast - Business Wire
QIAGEN NV : Deutsche Bank maintains a Buy rating - MarketScreener
Baptista Research Begins Qiagen Coverage at Hold - MarketScreener
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays - MSN
Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2031 - MarketScreener
Ex-Dividend Reminder: Comcast, Qiagen and HA Sustainable Infrastructure Capital - Nasdaq
QIAGEN Announces Managerial Share Transaction - TipRanks
Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships - MSN
QIAGEN Announces Election of Stephen Rusckowski as Chairman of S - GuruFocus
Qiagen (QGEN) Target Price Raised by B of A Securities | QGEN Stock News - GuruFocus
Qiagen stock reaches 52-week high at 48.24 USD - Investing.com
Barclays initiates Qiagen stock with overweight rating on diagnostics strength - Investing.com
Qiagen Announces BlackRock’s Significant Voting Rights Disclosure - TipRanks
Qiagen (QGEN) Just Flashed Golden Cross Signal: Do You Buy? - Nasdaq
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions - MSN
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - BioSpace
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - MSN
Qiagen’s Voting Rights Notification Highlights BlackRock’s Influence - TipRanks
BlackRock’s Significant Stake in Qiagen Revealed - TipRanks
Qiagen (QGEN) Partners with Gencurix to Enhance Oncology Diagnos - GuruFocus
Qiagen, Gencurix Launch Oncology Testing Development Partnership - MarketScreener
Qiagen and Gencurix partner for oncology tests (QGEN:NYSE) - Seeking Alpha
QIAGEN, GENCURIX announce QIAcuity Digital PCR IVD Assay Development Partnership - marketscreener.com
QGEN Stock Rises in After Market Following Partnership With Incyte - MSN
Qiagen and Incyte announce precision medicine collaboration - BioSpectrum Asia
Should You Add QIAGEN Stock to Your Portfolio for Now? - MSN
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Medical Device Network
QIAGEN, Incyte Partner to Develop NGS-Based Diagnostic Panel for Rare Blood Cancers - MarketScreener
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
QIAGEN and Incyte Announce Precision Medicine Collaboration to D - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) | QGEN Stock News - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Yahoo Finance
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - MSN
Qiagen Announces Significant Shareholding Notification - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Qiagen Discloses BlackRock’s Voting Rights Notification - TipRanks
Qiagen Reports Change in Voting Rights Held by BlackRock - TipRanks
Qiagen Announces BlackRock’s Significant Stake Notification - TipRanks
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - Yahoo Finance
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
QIAGEN (QGEN) Partners with Tracer Biotechnologies for MRD Assays - GuruFocus
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QGEN Partners with Tracer Biotechnologies to Advance Cancer Test - GuruFocus
Qiagen (NYSE:QGEN) Sees Large Increase in Short Interest - Defense World
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - marketscreener.com
Qiagen Nv (QGEN) 財務データ
収益
当期純利益
現金流量
EPS
12.12%
0.11%
大文字化:
|
ボリューム (24 時間):